COSCIENS Biopharma Q1 2024 Earnings Report $2.57 -0.14 (-5.17%) As of 04/4/2025 03:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings History COSCIENS Biopharma EPS ResultsActual EPS-$4.74Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACOSCIENS Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACOSCIENS Biopharma Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call ResourcesCSCI Earnings History Remove Ads COSCIENS Biopharma Earnings HeadlinesCOSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade OrderApril 1, 2025 | financialpost.comCOSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade OrderApril 1, 2025 | globenewswire.comForget 99% of the entire stock market. Trade this one stock insteadJeff Clark says he joined the top 1% of wealthy Americans by doing something radically simple — ignoring 99% of the stock market and trading just one specific gold stock. He calls it the “One Gold Stock Retirement” strategy. Through bull and bear markets alike, he’s used this same trade to rack up triple-digit gains — often outperforming gold itself. And he's not the only one: over 20,000 everyday investors have tapped into this approach to pursue financial freedom. Whether you’re starting with $100 or $1 million, this monthly trade could help you profit in any market — even during crashes.April 6, 2025 | InvestorPlace (Ad)COSCIENS Biopharma Faces Potential Delay in Year-End Filings Due to Merger ComplexitiesMarch 19, 2025 | tipranks.comCOSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting DocumentsMarch 19, 2025 | financialpost.comCOSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting DocumentsMarch 19, 2025 | gurufocus.comSee More COSCIENS Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like COSCIENS Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on COSCIENS Biopharma and other key companies, straight to your email. Email Address About COSCIENS BiopharmaCOSCIENS Biopharma (NASDAQ:CSCI), a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.View COSCIENS Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Lamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go Higher Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)The Goldman Sachs Group (4/14/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
